Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Optimization of antimicrobial treatment in sepsis.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022

Same author

Pharmacokinetics/Pharmacodynamics and tolerability of cefiderocol in the clinical setting.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022

Same author

The pharmacodynamic bases of the prescription of antimicrobials.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2019

Same author

Ceftobiprole: pharmacokinetics and PK/PD profile.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2019

Same author

Pharmacokinetics of anidulafungin in critically ill patients with Candida peritonitis.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2019

Same author

[In Process Citation].

Archivos de la Sociedad Espanola de Oftalmologia·2015

Search research articles

Related Experiment Video

Updated: May 14, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

[Ranibizumab versus bevacizumab. Pharmacological considerations].

J R Azanza Perea¹, A García Layana

¹Servicio de Farmacología Clínica, Clínica Universidad de Navarra, Pamplona, España; Sociedad Española de Retina y Vítreo (SERV).

Archivos De La Sociedad Espanola De Oftalmologia

|February 6, 2013

Summary

Intravitreal bevacizumab can cause systemic effects due to its full-length IgG structure, unlike ranibizumab, a fragment that remains localized in the eye.

Related Experiment Videos

Last Updated: May 14, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Area of Science:

Ophthalmology
Pharmacology
Immunology

Background:

Bevacizumab, a full-length IgG antibody, can cross ocular barriers after intravitreal administration.
This crossing leads to plasma concentrations affecting vascular endothelial growth factor (VEGF) and potential systemic effects.
The FcRn receptor facilitates the transport of full-length IgGs across tissues.

Purpose of the Study:

To compare the pharmacokinetic and safety profiles of intravitreal bevacizumab and ranibizumab.
To elucidate the mechanisms behind potential systemic absorption of intravitreal anti-VEGF agents.

Main Methods:

Analysis of bevacizumab's full-length IgG structure and its interaction with FcRn receptors.
Comparison with ranibizumab, an IgG fragment lacking the Fc region.
Evaluation of formulation differences and their impact on intravitreal administration.

Main Results:

Bevacizumab's FcRn binding allows transport into systemic circulation, posing a risk of off-target effects.
Ranibizumab, lacking the Fc region, does not bind FcRn receptors and exhibits no systemic bioavailability.
Bevacizumab's intravenous formulation requires manipulation for intravitreal use, raising sterility and efficacy concerns.

Conclusions:

Intravitreal bevacizumab carries a risk of systemic exposure and associated adverse effects.
Ranibizumab offers a safer alternative due to its localized ocular action and specifically designed formulation.
Understanding drug structure and receptor interactions is crucial for optimizing intravitreal therapies.